Neurocrine Biosciences announced two deals in the space of 24 hours with Abbott, for its experimental drug elagolix, and with Boehringer Ingelheim, to discover and develop small molecule G-protein coupled receptor 119 (GPR 119) agonists to treat type 2 diabetes and other indications.